Proacta S.A., a bioinformatics company listed on the NewConnect market and developing solutions for the healthcare sector, has established a Medical Board. The permanent advisory body, composed of recognised clinicians specialising in diabetology, endocrinology and internal medicine, will support the development of projects in medtech, clinical AI/ML and tools used in diagnostic and therapeutic processes.
The initiative confirms the clinical credibility of Proacta’s solutions and forms part of the company’s current stage of development, in which clinical validation, commercialisation of proprietary products and responsible implementation of data-driven technologies are becoming increasingly important.
The Medical Board of Proacta S.A. includes experts combining clinical practice, scientific experience and competence in the validation of medical solutions. The Board is chaired by Dr. Michał Lis, MD, PhD, a specialist in internal medicine, diabetology and endocrinology, Head of the Department and Clinic of Internal Medicine, Endocrinology, Diabetology and Metabolic Diseases at Czerniakowski Hospital.
The Board also includes Dr. Olga Turowska, MD, PhD, a diabetologist and specialist in internal medicine, Head of the Warsaw Specialist Centre for the Treatment of Civilisational Diseases, involved in the development of modern glucose monitoring technologies; Dr. Kamil Wrzosek, MD, a diabetologist and specialist in internal medicine, Deputy Head of the Department of Internal Medicine, Endocrinology, Diabetology and Internal Diseases at Czerniakowski Hospital, with experience in clinical trials; and Dr. Paweł Zugaj, MD, physician and medical consultant at Proacta S.A., responsible, among other things, for substantive verification of diagnostic algorithms and assessment of the clinical usefulness of data in the company’s R&D projects.
“We are developing projects at the intersection of technology, medicine and science. Our advantage lies in the ability to combine bioinformatics expertise, clinical AI/ML and the creation of specialised software for the healthcare sector. This business profile requires constant cooperation with representatives of the clinical and scientific communities, particularly at the stage of validating product assumptions, assessing implementation potential and defining further development directions. Establishing the Medical Board allows us to confront our solutions even more effectively with expert knowledge and the real needs of physicians, medical facilities and patients,” said Maciej Grzywacki, Vice-President of Proacta S.A.
The Medical Board of Proacta S.A. acts as a permanent advisory and validation body, with its work directly linked to the development of the company’s ecosystem of certified medical devices. Its tasks include cyclical validation and clinical assessment of Proacta’s solutions, including systematic verification of algorithms, results and interpretations generated by the Smart Lab ecosystem.
The Board also provides ongoing clinical feedback, participates in designing subsequent stages of the product roadmap in line with the Digital Trust 2026–2028 strategy, and strengthens the Evidence-Based Medicine approach on which the company bases the development of its medical technologies. Permanent cooperation with experts in diabetology, endocrinology and metabolic diseases is intended to support both the functional development of products and their clinical credibility.
“Our products are moving from the development phase to practical implementation and market validation. They are already finding real application in the medical environment, as shown by the first commercial implementation of the Digital Breast Cancer Unit, a platform supporting breast cancer diagnosis and treatment through the integration of medical data, clinical guidelines and predictive models. At the same time, we are developing the Dbam o siebie Smart Lab platform, a certified medical device that analyses laboratory and telemedical data and generates personalised health reports supporting prevention and predictive medicine. In this process, it is particularly important that technological innovations are developed responsibly, in line with the expectations of the medical market and in a scalable model. Cooperation with experts will provide us with additional support in assessing project potential, prioritising activities and building solutions that respond to specific challenges in the healthcare system,” added Paweł Ciesielka, President of the Management Board of the company.
The activity of the Medical Board is intended to support Proacta’s long-term competitive advantage by ensuring constant access to the knowledge of practising medical specialists and ongoing assessment of the solutions under development. Validation of algorithms and medical devices by clinical experts increases the credibility of the company’s technologies and distinguishes them from traditional IT solutions and general AI tools.
Cooperation with recognised clinicians also creates an important barrier to entry for competitors, as it combines expert resources that are difficult to replicate with an organised quality assessment process. Regular clinical evaluation and ongoing consultations with physicians may accelerate product development, support certification processes and increase the commercial potential of Proacta’s solutions.
